Answers are grounded in this paper and cite their sources.
Objectives: Tumour necrosis factor alpha (TNF-α) inhibitors have significantly improved outcomes in rheumatoid arthritis (RA); however, up to 30% to 40% of patients show inadequate response. This highlights the need for predictive biomarkers to guide personalised therapy. Blood transcriptome profiling is a promising strategy for identifying gene signatures linked to treatment response, though prior studies have shown inconsistent results due to technical and biological heterogeneity. Methods: effect size, and the full gene set. External validation was performed using an independent dataset. Results: The recurrent gene set showed strong and consistent predictive performance across machine learning models. Notably, several genes overlapping with the patent and top-ranked sets were among the top contributors, supporting their potential value for future diagnostic applications. Conclusions: Our study demonstrates the feasibility of transcriptome-guided prediction of response to TNF-α inhibitors in RA. The integration of meta-analysis and machine learning provides a strong foundation for the development of precision diagnostic tools to support personalised treatment strategies in clinical practice.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: